USDA confirmed highly pathogenic Avian influenza in Pennsylvania and Utah
On Apr. 16, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Idaho officials confirmed highly pathogenic Avian influenza
On Apr. 15, 2022, The Idaho State Department of Agriculture (ISDA) announed it had received confirmation of multiple…
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
On Apr. 14, 2022, Merck announced that V116, the companyﾒs investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
FDA authorized first COVID-19 diagnostic test using breath samples
On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
Regeneron antibody cocktail approved by European Commission to treat and prevent COVID-19
On Nov. 12, 2021, Regeneron announced that the U.S. Food and Drug Administration had extended by three months…
FDA announced legislation clarifying the agency can regulate tobacco products containing nicotine from any source
On Apr. 13, 2022, the U.S. Food and Drug Administration announced that the legislation clarifying the agency can…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Highly pathogenic avian influenza reported in Alberta
On Apr. 12, 2022, the Province of Alberta poultry reported that farms had tested positive for highly pathogenic…
CureVac and GSK entered into Pandemic preparedness contract with German government Candidate, CV2CoV
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
Veruﾒs novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in interim analysis of phase 3 study
On Apr. 11, 2022, Veru announced positive efficacy and safety results from a planned interim analysis of the…
USDA confirmed highly pathogenic Avian influenza in Montana
On Apr. 8, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed the…
BioNTech granted pandemic preparedness contract by German Federal Ministry of Health
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
Novavax and Serum Institute of India received EUA for COVID-19 vaccine in Thailand
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
Major study linked breast cancer treatment with increased risk of cardiovascular disease
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
NIH funded new tuberculosis research advancement centers
On Mar. 9, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced four grant awards to…
USDA confirmed highly pathogenic Avian influenza in Texas
On Apr. 3, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
Biotechnology | Diagnostics | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW Medicine
On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…
NIH began clinical trial evaluating second COVID-19 booster shots in adults
On Mar. 31, 2022, the National Institutes of Health (NIH) and Moderna announced a phase 2 clinical trial…
Ivermectin ineffective in large study of treatment among patients with Covid-19
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Novavax submitted request to expand conditional Marketing Authorization of COVID-19 vaccine in the EU to adolescents
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
USDA confirmed highly pathogenic Avian influenza in Massachusetts, Wyoming, North Carolina, Ohio and North Dakota
On Mar. 30, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service confirmed the…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
Moderna received FDA approval for EUA of 2nd booster dose of its COVID-19 vaccine, mRNA-1273
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
On Mar. 25, 2022, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP)…
WHO established the Global Centre for Traditional Medicine in India
On Mar. 25, 2022, the WHO and the Government of India signed an agreement to establish the WHO…